https://www.businesswire.com/news/home/20221031005225/en/Verge-Genomics-Initiates-First-In-Human-Dosing-in-Phase-1-Trial-of-VRG50635-a-Novel-Therapeutic-for-Amyotrophic-Lateral-Sclerosis
0
0
10/31/22 at 10:30am
Organization
Business Wire
44 words
0
Comments
Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform dr
You are the first to view
Create an account
or login to join the discussion